Chipscreen(SH:688321) Zheng Quan Ri Bao Zhi Sheng·2025-08-26 13:36Core Viewpoint - Shenzhen Micron Biotech Co., Ltd. reported significant growth in revenue and profit for the first half of 2025, driven by strong sales of its new drugs and a robust pipeline of innovative therapies [1][2]. Financial Performance - Revenue for the first half of 2025 reached 407 million yuan, representing a year-on-year increase of 34.56% [1]. - The net profit attributable to shareholders was 29.59 million yuan, marking a turnaround from previous losses [1]. Product Performance - Sales of Sigleptin (Duloxetine) and Sidabenamine (Ipusab) saw substantial growth, with increases of 125.70% and 15.14% year-on-year, respectively [1]. - The clinical data for Xioroni, targeting pancreatic cancer, showed a promising 6-month progression-free survival (PFS) rate of approximately 80% [1]. Research and Development - The company has introduced a series of global first-in-class new molecular entities targeting major diseases, including next-generation cancer immunotherapy, Alzheimer's disease, high-quality weight loss, and fibrotic diseases [1]. - Micron Biotech has integrated AI-assisted design with chemical genomics to enhance early-stage research projects [2]. Strategic Focus - The company is focusing on differentiated innovation pipelines and sustainable business strategies as key drivers of long-term value [2]. - Future strategic priorities include expanding into oncology and metabolic disease sectors while addressing unmet clinical needs in neurodegenerative and autoimmune diseases [2]. Market Expansion - In the first half of 2025, Micron Biotech actively developed new retail channels to accelerate the commercialization of innovative drugs, creating a multi-channel marketing strategy that includes online, offline, hospital, and non-hospital sales [1].